Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
SHANGHAI, May 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its...
Gastops Receives Investment from RTX for Next Generation Monitoring Technologies
Investment made possible by Canadian Industrial and Technological Benefits Policy (ITB) OTTAWA, ON, May 29, 2025 /PRNewswire/ -- Gastops Ltd. is announcing a joint agreement under Canada's Industrial and Technology Benefits (ITB) policy for a...
CANGO Mobility Receives Frost & Sullivan's 2025 European Customer Value Leadership Award for Excellence in Telematics Solutions
CANGO is recognized for driving innovation and delivering customer-centric telematics solutions that optimize fleet performance, enhance connectivity, and support software-defined vehicle strategies. SAN ANTONIO, May 28, 2025 /PRNewswire/ -- Frost...
U Power Limited Receives "Beyond Impact Award" at the 5th BEYOND International Technology Innovation Expo in Macau
Beyond Impact Award recognizes companies with substantial contributions to the environment, society, economy, and technology, aligning with the UN's Sustainable Development Goals SHANGHAI, May 27, 2025 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR)...
ZYLOX Unicorn™ Vascular Closure Device Receives Regulatory Approval in Indonesia
HANGZHOU, China, May 27, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. ("Zylox-Tonbridge" or the "Company") today announced that its proprietary ZYLOX Unicorn™ Vascular Closure Device (VCD) has received regulatory approval in...
Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC
SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from...
Eason Technology Limited Receives Notification from NYSE Regarding Delayed Form 20-F Filing
HONG KONG, May 23, 2025 /PRNewswire/ -- Eason Technology Limited ("Eason Technology" or the "Company") (NYSE: DXF) today announced that it received a notice from NYSE Regulation indicating that the Company is not in compliance with the continued...
China Liberal Education Holdings Limited Receives Additional Nasdaq Staff Determination Letter of Delinquency
BEIJING, May 23, 2025 /PRNewswire/ -- China Liberal Education Holdings Limited ("China Liberal" or the "Company") (Nasdaq: CLEU), a China-based company that provides technological consulting services for smart campus solutions and other educational...
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
YUFLYMA ® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira ® (adalimumab) biosimilar [1] Celltrion previously received interchangeability (IC) designation for YUFLYMA® (adalimumab-aaty) in prefilled...
NaaS Technology Inc. Receives Notification of Non-Compliance from Nasdaq Regarding Late Filing of Annual Report on Form 20-F
BEIJING, May 22, 2025 /PRNewswire/ -- NaaS Technology Inc. (Nasdaq: NAAS) ("NaaS" or the "Company"), the first U.S. listed EV charging service company in China, today announced that it received a Notice of Non-Compliance (the "Notice") from Nasdaq...